Non-Sterile Compounding Pharmacy Market – Overview
The U.S. & Europe non-sterile compounding pharmacy market is expected to grow at a CAGR of 2.65% during the forecast period. Compounding involves the customization of the medicine based on the physician prescription. The pharmacist customizes the dosage or strength and reformulates the drug by excluding unwanted ingredients to which the patient is allergic, or may change the form of the medicine for the patients who are unable to swallow the oral medications.
Non-sterile compounding requires clean environment for the preparation of drugs or other products. However, maintaining clean workplace is essential during the formulation of non-sterile compounding as per the standard specified by the regulatory bodies governing the use of ingredients. About 125 simple formulas for non-sterile compounds are formulated in the U.S. Pharmacopeia. The pediatricians and veterinarians commonly prescribe the non-sterile compounding products.
In pharmacy, the compounding pharmacists have to comply with the standards set by the regulatory authorities. The Drug Enforcement Administration (DEA) monitors the use of any controlled substances for the preparation of compounded medications. The U.S. Pharmacopeia (USP) Convention issues standards that apply to the compounding.
Taste the market data and market information presented through more than 55 market data tables and figures spread over 101 pages of the project report. Avail the in-depth table of content (TOC) & market synopsis on “Non-sterile compounding pharmacy market research report–U.S. & Europe forecast till 2023.”
Request Sample copy at https://www.marketresearchfuture.com/sample_request/4669
Regional Analysis:
America is the largest market for non-sterile compounding pharmacy owing to the rising demand for customized medicine, and rising number of hospital-based compounding pharmacies. As per the Center for Diseases Control and Prevention (CDC) in 2015, 30.3 million Americans, i.e., 9.4% of the population had diabetes. Additionally, 1.25 million American children and adults had type 1 diabetes. Key market players are engaged in a number of strategy such as mergers & acquisitions, for instance, Fresenius Kabi AG, a company based in Germany, acquired the U.S. based generic drugs manufacturer Akorn, Inc. to expand its wings in the U.S.
Europe is the second largest non-sterile compounding pharmacy market. In Europe, the number of chronic diseases such as diabetes, drug allergies, and rising awareness about the availability of compounded medications is increasing. Furthermore, availability of funds for research and development activities strengthens the market growth. According to European Academy of Allergy and Clinical Immunology (EAACI), around 2.6% hospitalization registered due to adverse drug effects while the prevalence of drug allergy in the hospitalized patients is around 10% in the Europe. As per European Academy of Allergy and Clinical Immunology, 150 million European Union (EU) citizens have the chronic allergic disease.
Non-Sterile Compounding Pharmacy Market – Top Vendors
Some of the key players in this market are Fagron (the Netherlands), B.Braun Melsungen AG (Germany), Fresenius Kabi AG (Germany), TRUE NATURE HOLDING, INC (U.S), Dougherty’s Pharmacy Inc. (U.S.), and PHARMEDIUM (U.S.).
Non-sterile compounding requires clean environment for the preparation of drugs or other products. However, maintaining clean workplace is essential during the formulation of non-sterile compounding as per the standard specified by the regulatory bodies governing the use of ingredients. About 125 simple formulas for non-sterile compounds are formulated in the U.S. Pharmacopeia. The pediatricians and veterinarians commonly prescribe the non-sterile compounding products.
Segmentation:
The U.S. & Europe non-sterile compounding pharmacy market is segmented by product, application, and end user.
By type, the market is segmented into oral medication, topical medication, otologic/nasal medication, and others. The oral medications are further segmented into solid and liquid preparations. The topical medications include ointments, creams, gels, pastes, and others.
By application, the market is segmented into pain medication, hormone replacement therapy, and others.
By end user, the market is segmented into hospitals, compounding pharmacy, and others.
Key findings:
- Pain management is expected to account for the largest market share of 50.3% in the U.S. and Europe non-sterile compounding pharmacy market
- Hospitals occupy the largest market share and is expected to reach USD 871.97 million by 2023
Major TOC of Non-Sterile Compounding Pharmacy Market – U.S. & Europe Forecast Till 2023:
1 Report Prologue
2 Market Introduction
3 Research Methodology
4 Market Dynamics
5 Market Factor Analysis
6 U.S. & Europe Non- Sterile Compounding Pharmacy Market, By Product
7 U.S. & Europe Non- Sterile Compounding Pharmacy Market, By Application
8 U.S. & Europe Non- Sterile Compounding Pharmacy Market, By End User
9 U.S. & Europe Non- Sterile Compounding Pharmacy Market, By Region
10 Company Landscape
TOC CONTINUED…
Browse Complete 101 Pages Premium Research Report Enabled with Respective Tables and Figures at https://www.marketresearchfuture.com/reports/non-sterile-compounding-pharmacy-market-4669
About Market Research Future:
At Market Research Future (MRFR), we enable our customers to unravel the complexity of various industries through our Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.
Media Contact
Company Name: Market Research Future
Contact Person: Abhishek Sawant
Email: Send Email
Phone: +1 646 845 9312
Address:Market Research Future Office No. 528, Amanora Chambers Magarpatta Road, Hadapsar
City: Pune
State: Maharashtra
Country: India
Website: https://www.marketresearchfuture.com/reports/non-sterile-compounding-pharmacy-market-4669